

DARZALEX FASPRO®

(daratumumab and hyaluronidase-fihj)


What is the recommended dosing for DARZALEX FASPRO to treat high-risk smoldering multiple myeloma?

DARZALEX FASPRO dosage for high-risk smoldering multiple myeloma¹

- DARZALEX FASPRO is used **on its own to treat** adult patients with high-risk smoldering multiple myeloma.
- The recommended dose of DARZALEX FASPRO is **1800 mg/30,000 units** (1800 mg daratumumab and 30,000 units hyaluronidase).
- Do not receive DARZALEX FASPRO **if you have a history of a severe allergic reaction** to daratumumab, hyaluronidase or any of the ingredients in DARZALEX FASPRO.

Please refer to the full PRESCRIBING INFORMATION and PATIENT INFORMATION for complete indications and usage.

Dosing schedule of DARZALEX FASPRO for high-risk smoldering multiple myeloma¹



DARZALEX FASPRO®

(daratumumab and hyaluronidase-fihj)

What is the recommended dosing for DARZALEX FASPRO to treat high-risk smoldering multiple myeloma?

How will I receive DARZALEX FASPRO?¹



DARZALEX FASPRO will be given to you by your healthcare provider as an **injection under the skin** (subcutaneous injection), in the stomach area (abdomen).



DARZALEX FASPRO is injected over **3 to 5 minutes**.



Your **healthcare provider will decide** the time between doses as well as how many treatments you will receive.



Your healthcare provider will give you medicines before each dose of DARZALEX FASPRO and after each dose of DARZALEX FASPRO to **help reduce the risk** of serious allergic reactions and other reactions due to release of certain substances by your body (systemic).



If you miss any appointments, **call your healthcare provider as soon as possible** to reschedule your appointment.

This information is provided ONLY in response to your request and is not intended as medical advice, to promote the use of our product, or suggest using it in any manner other than as described in the PRESCRIBING INFORMATION. All decisions regarding your medical treatment should be made with your healthcare professional(s). Please contact your healthcare professional(s) to discuss the information in this response.

Please refer to the attached full PRESCRIBING INFORMATION, and the PATIENT INFORMATION for DARZALEX FASPRO.¹

1. DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc;

<https://www.injlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf>